Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Syndax Pharmaceuticals (SNDX) Income from Continuing Operations (2016 - 2020)

Syndax Pharmaceuticals has reported Income from Continuing Operations over the past 6 years, most recently at 19860000.0 for Q4 2020.

  • Quarterly results put Income from Continuing Operations at 19860000.0 for Q4 2020, down 39.81% from a year ago — trailing twelve months through Dec 2020 was 71423000.0 (down 24.13% YoY), and the annual figure for FY2025 was 250360000.0, up 20.16%.
  • Income from Continuing Operations for Q4 2020 was 19860000.0 at Syndax Pharmaceuticals, roughly flat from 19853000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for SNDX hit a ceiling of 8358000.0 in Q2 2016 and a floor of 19860000.0 in Q4 2020.
  • Median Income from Continuing Operations over the past 5 years was 15067500.0 (2017), compared with a mean of 15409000.0.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 145.93% in 2016 and later increased 26.52% in 2019.
  • Syndax Pharmaceuticals' Income from Continuing Operations stood at 10873000.0 in 2016, then crashed by 74.99% to 19027000.0 in 2017, then dropped by 1.61% to 19333000.0 in 2018, then increased by 26.52% to 14205000.0 in 2019, then crashed by 39.81% to 19860000.0 in 2020.
  • The last three reported values for Income from Continuing Operations were 19860000.0 (Q4 2020), 19853000.0 (Q3 2020), and 16610000.0 (Q2 2020) per Business Quant data.